Skyhawk develops a broad portfolio of small molecule RNA-modifying drug candidates that have the potential to improve the lives of patients by directly addressing the causes of disease.

Our wholly-owned pipeline includes programs across neurodegenerative, oncology, neuromuscular, fibrosis and other disease types. Many of our programs are against targets formerly considered “undruggable” for traditional protein-targeting mechanisms.